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Accepted 7 May 2012AbstractObjective: Cervicovaginitis is a highly prevalent disease that is a burden on healthcare globally. Immediate and adequate treatment can eradicate
the infection and block subsequent complications. The feasibility of achip-based multiplexed immunoassay using liposomal nanovesicles was
tested.
Materials and Methods: A multiplexed immunoassay chip containing five antibodies for five pathogens (Chlamydia trachomatis, Escherichia
coli, Neisseria gonorrhoeae, Streptococcus agalactiae, and Candida albicans) was established and tested. Four patients with spiking of
candidiasis were enrolled. The difference between positive and negative readings was evaluated using the paired Student t test.
Results: The detection threshold of Candida in this microarray was 100,000 CFU/mL in a vaginal sample, and the time required for the whole
procedure was 3 hours. The testing of the four patients showed 100% for both sensitivity and specificity.
Conclusion: This microarray chip was a rapid, easy, inexpensive and sensitive tool for detecting female lower genital tract Candida infection in a
one-time vaginal sampling process, although the data on the four other pathogens were still unavailable. A larger population study is encouraged
to test the validity of this multiplexed immunoassay chip.
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Lower genital tract infection in women may be one of the
most common diseases in gynecological outpatient clinics [1].
The majority of lower genital tract infections are caused by
mixed pathogens, although some dominant species might be
identified. Since the infections are complicated, and immedi-
ate and accurate diagnoses are not always obtained, treatment
with appropriate antibiotics is often delayed [2]. This might
lead to progression into severe conditions, such as pelvic in-
flammatory diseases (PIDs) [3], or much moresevere situa-
tions, including infertility, ectopic pregnancy, preterm labor,
and chronic pelvic pain [4]. Therefore, to avoid the occurrence
of these severe sequelae, an early and accurate identification of
the causal pathogens is important. However, many factors
might interfere with the achievement of this goal, including
clinical ignorance, insufficient education, poor communication
between professionals, non-availability of a user-friendly
detection tool, and the lag-time required for definite diag-
nosis [5].
The syndrome approach combined with microscopic ex-
amination and ordinary culture has traditionally been a gold
standard in the diagnosis of female lower genital tract infec-
tion. In developing countries or medical resource-deficient
societies, syndrome judgment is most frequently used for
diagnosis of lower genital tract infections, although both
sensitivity and specificity are low (w 40%) [5e8]. To improve
the low sensitivity and specificity of syndrome judgment,
microscopic examination might be added. In fact, the Pap
smear is a well-established tool not only for cervical cytology
screening for cervical neoplasm, but also possibly for identi-
fication of infectious pathogens. Unfortunately, it is not rec-
ommended for the diagnosis of female lower genital tract
infection by the World Health Organization due to its low
detection rate [6]. Only ordinary culture is a standard proce-
dure, and it is often used in comparison with other diagnostic
tools, such as the Gram stain [9], and immunoassay or nucleic
acid amplification tests (NAATs) [10], and of importance, it is
also useful for identification of resistant strains of pathogens
and provides a suggestion for the use of antimicrobial agents.
However, culture is also affected by many factors [11],
including the needs of the specialized culture media and the
sometimes strict culture conditions, skilled staff and at least
72-hour culture time [12]. In fact, it is not easy to select
specialized culture media and these various kinds of culture
media might not be readily available, especially for first-line
physicians.
In recent years, some molecular techniques have been
developed to aid the diagnosis of lower genital tract infection
when they are simultaneously used with syndrome, micro-
scopic examination and culture methods, in order to provide
prompt treatment and further antimicrobial susceptibility
testing [13e15]. For example, the polymerase chain reaction
method for the detection of chlamydia infection has been used
frequently in fertility centers. NAATs have been reported to be
a gold standard [13,14] in the detection of various lower
genital tract infection pathogens, based on the near 95e100%specificity and 95% sensitivity of the tests [10]; of most
importance, there have been relatively consistent results, even
among different NAATs [13]. Although NAATs seem to be
good diagnostic tools for diagnosis of lower genital tract in-
fections, NAATs are not accepted in clinical practice because
of their expense and complex techniques. In addition, highly
trained staff and delicate and very expensive equipment are
needed to achieve the high specificity and sensitivity. These
factors hinder the wide use of NAATs in developing countries
[16].
To overcome the high cost and complex procedures of the
NAATs, a number of different immunoassay kits have been
developed for the detection of lower genital tract infection
[17]. The main advantage of immunoassays is that they are
rapid, simple, and cheap, and of importance, microscopy is not
required, although the sensitivity is low (50e85%) [17,18].
Immunoassays might outperform other standard tests in high-
risk sexually transmitted disease groups, including sexual
workers and/or those with low return rates in developing
countries [18], and provide an appropriate therapeutic plan in
the management of the infection [19,20], based on the possi-
bility of a single approach to detect many potential pathogens
[19e22].
The advances in immunoassay include high throughput as-
says and microarray chip fabrication [23,24]. The aim of this
study was to explore the possibility of a single vaginal sampling
to detect many pathogens at the same time. We used the tech-
nique of liposomal nanovesicles to build up a signal amplifying
system, which has been reported to increase the sensitivity rate
of immunoassays [25e28], and antibody microarray to detect
many pathogens with a single test [24,29,30].
Materials and methodsReagentsReagents, including dipalmitoylphosphatidylethanolamine
(DPPE), N-succinimidyl-S-acetylthioacetate (SATA), triethyl-
amine (TEA), chloroform, methanol, dipalmitoylphosphati-
dylglycerol (DPPG), dipalmitoylphosphatidylcholine (DPPC),
cholesterol, lissamine rhodamine B (LRB), and sulforhod-
amine B (SRB) were obtained from Sigma, Northbrook, IL,
USA.Signal amplifying liposomal nanovesicle system
Liposome preparation
DPPE and SATAwere first dissolved in a solvent consisting
of 21 mL TEA and 3 mL chloroform. The mixture was kept at
room temperature (RT) for 30 minutes. The DPPE-SATA so-
lution was then repeatedly resolved by chloroform and dried
with N2(g) at least twice. Finally, the 3.2 mmol ATA tagged
DPPE was formed and resolved in 0.5 mL of chloroform. The
other components of the liposome, including DPPG, DPPC,
cholesterol, and LRBeDPPE were dissolved with organic
solvent (0.75 mL chloroform and 0.25 mL methanol, and then
1.6 mmol of ATA-DPPE was added and mixed in a round flask
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the flask after the total 40 mmol lipid solution was dried with
N2(g). A proper volume of 60 mL 0.2 mM SRB solution was
added into the flask to cover the entire gel-like membrane, and
then the flask was placed in a 60C water bath for encapsu-
lation for about 1 hour.
After the SRB solution was encapsulated inside the lipid
bilayers, the solution was extruded through the 50-nm mem-
brane in-built extruder 30 times at 60C to form a 50-nm
liposome. In the end, free SRB was separated with the SRB-
encapsulated liposome by size exclusion chromatography
with a sepharose CL-4B (GE Protein analyzer reagents) resin
column. SRB-encapsulated liposome was visually observed in
the lower fraction since it was much larger than the free SRB.
The final 40 mmol liposome consisted of 5% DPPG, 45.7%
DPPC, 45% cholesterol, 0.3% LRB-DPPE, and 4% ATA-
DPPE with 0.2 mM SRB inside.
Conjugation of neutravidin to ATA-tagged liposome
There were five steps in this process, including: (1) deriv-
atization of neutravidin using polyethylene glycol (PEG)
compounds as spacer arms; (2) de-protection of the thiol group
on the liposome surface; (3) the conjugation reaction; (4) the
quench reaction to remove the excess sulfhydryl group; and,
(5) size exclusion chromatography.
Derivatization of neutravidin
This step would eventually result in the combination of
neutravidin and SM(PEG)24 (succinimidyl-N-maleimido-) by
removing the succinimidyl group of SM(PEG)24, and
revealing the other maleimide group end of SM(PEG)24.
Neutravidin (15.667 nmol) were dissolved with 1 mL of
phosphate-buffered saline (PBS) along with 235 nmol (15-fold
greater than the amount of neutravidin) of SM(PEG) 24
(Thermo, Rockford, IL) in a round-bottomed flask with a pH
value adjusted to approximately 6e8, and on the shaker at
120 rpm for 2 hours. After the 7K, 5 mL of zeba desalting spin
column (Pierce, USA) was prepared, the solution was loaded
into the column to separate free SM(PEG)24 from SM(PEG)24-
tagged neutravidin by centrifuge at 1000 rpm for 2 minutes.
De-protection of the thiol group on liposome
This step prepared the sulfhydryl groups on the surface of
the liposome for future covalent binding. One milliliter of
liposome in a concentration of 4.3 mmol/mL (about 250-fold
the amount of neutravidin) was added to the round-bottomed
flask with 0.1 mL of the hydroxylamine solution. The flask
was then flushed with N2 for 1 minute and immediately sealed
up. It was then placed on a shaker for 2 hours until the
deacetylation reaction of ATA on the liposome surface was
completed.
Conjugation reaction
This step was the final conjugation of neutravidin to the
ATA-tagged liposome. After both SM(PEG)24-tagged neu-
travidin and the de-protected liposome were prepared, the two
solutions were to be mixed together. The pH value of theliposomes was adjusted to about pH 7 (6.5e7.5) by adding
aliquots of 0.5M potassium phosphate, and then the 1 mL of
maleimide-derivatized neutravidin solution was added into the
flask for conjugation. The mixture was put on a shaker at RT
for 3.5 hours and then transferred to a shaker in a 4C freezer
overnight.
Quench reaction
This step reversed the second step and extinguished the
unreacted sulfhydryl groups on the surface of the liposome.
N-ethylmaleimide (100 mM, 0.0125 g/mL, Sigma) in potassium
phosphate (0.02 M, pH 7) was prepared. N-ethylmaleimide in
the same amount as the liposomes used for the conjugation was
added into the flask and kept on the shaker for 30 minutes.
Size exclusion chromatography
This step removed the unreacted maleimide-derivatized
neutravidin from neutravidin-tagged liposomes. A Sephadex
CL-4B column was equilibrated with Tris-buffered saline
(TBS)-sucrose buffer (51.77 g sucrose) with adjustment of the
pH to 7.4. The desired fraction was eluted right after the void
volume. The fractions were collected and stored in a 4C
freezer for future use.
Validation of neutravidin conjugation on liposomes
To confirm the conjugation of neutravidin on liposomes, the
final product after conjugation, the original liposomes and a
96-well black plate were used. Two rows of wells with three
replicates from well E1 to E3 and F1 to F3 were coated with
20 mg/mL rabbit anti-Escherichia coli with biotin, whereas the
third row from well G1 to G3 was coated with rabbit anti-
Escherichia coli without biotin. After a 1-hour coating pro-
cedure processed on a shaker at 50 rpm at RT, the antibody
solution was cleared out and 0.2 mL of blocking buffer was
added to each well and placed on a shaker for another 30
minutes. After blocking was finished, the blocking buffer was
cleared out and each well washed with 0.2 mL of blocking
buffer three times, and then different samples were put into the
wells. Samples of neutravidin-conjugated liposome were
added to the wells from E1 to E3 (Row 1) and G1 to G3 (Row
3) at a concentration of 236.364 nmol/mL. For wells F1 to F3
(Row 2), free liposome without neutravidin was added at a
concentration of 78.788 nmol/mL. After incubation for 1 hour
at RT on a 50 rpm shaker, the sample solutions were cleared
out and the wells were washed with blocking buffer three
times. Finally, the wells with blocking buffer were read with a
spectrophotometer with Gen5 at OD540/590.Fabrication of antibody chips and chips assay
Antibody chip printing
Five pathogen-specific polyclonal antibodies, including
rabbit anti-Streptococcus agalactiae (AbD seroTec, Oxford,
UK), rabbit anti-Chlamydia trachomatis (AbD seroTec, Ox-
ford, UK), rabbit anti-Neisseria gonorrhoeae (GeneTex,
Irvine, CA, USA), rabbit anti-Escherichia coli (AbD seroTec,
Oxford, UK), and rabbit anti-Candida albicans (Fitzgerald,
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to print on an aldehyde glass slide (Baio) in an eight by two
cassette arrangement (ArrayIt, California, USA) with an
automatic arrayer (SmartArrayer 136, CapitalBio) in a 4C
cold room. After the chips were printed, they were kept at 4C
for at least 12 hours to immobilize the proteins, and then the
chips were stored in a 20C freezer. The three controls
included Cy3-labeled immunoglobulin G (IgG) (Jackson
ImmunoResearch Europe Ltd., Suffolk, UK), goat anti-rabbit
IgG, and biotin anti-Escherichia coli (Jackson ImmunoR-
esearch Europe Ltd., UK). Various patterns with different
combinations of these five antibodies and three positive con-
trols were designed for this purpose.
Chip assay
Before the examination procedure, the chip was placed up-
side down inmultidishes full of TBSwith 5%Tween 20 (TBST)
briefly without touching the printed surface to wash out the un-
immobilized antibodies. A cover slide and a hybridization
cassette from ArrayIt, which could contain 16 samples on one
chip without contamination were then reassembled manually
and 5mL of 3%bovine serum albumin (BSA)was added to each
well as a blocking buffer. Then the cassette was put on a 3D
micro-shaker for 2 hours at RT. Before the chip was used, all
wells werewashed quickly with 1%BSATBST, 30 mL per well.
Pathogen or antigen samples of about 90mLwere added onto the
side of the separate chipswith a cover slide and then the chipwas
incubated in BioMixer at 15 rpm at RT for 1 hour. The chip was
then washed with 5 mL of 1% BSATBST quickly upside down,
gently shaken by hand and then washed twice by washer with
TBST, at 15 rpm for 5 minutes each time. Detecting antibody in
the amount of 90 mL of 0.00025 mg/mL was added and the chip
was incubated in a BioMixer at 15 rpm at RT for 1 hour. The
washing procedurewas repeated again. Then the chipwas rinsed
with 5mL of TBS-sucrose (51.77 g) for 1minute in the shaker at
50 rpm.Liposome solution (90mL)was finally added to the chip,
which was then incubated in a BioMixer at 15 rpm at RT for 1
hour. The chip was then washed with 5 mLTBS-sucrose in the
shaker at 75 rpm, at RT, for 10 minutes, and then washed two
times in the washer with TBS-sucrose (51.77 g) for 5 minutes
each time at 75 rpm. The chip in the hood was stood on the side
of the hood for 30 minutes to dry out.Validation of the liposomal amplifying system on chipsThe chips were composed of five different antibodies in a
concentration of 0.125 mg/mL with and without biotin. Cy3
was used as the only positive control and all spots consisted of
four replicates. Then the chip assay was carried out with the
neutravidin-conjugated liposomes only, without the addition of
a pathogen or detecting antibody.Validation of the antibody-antigen reaction on chipsChips composed of capture antibody in two different con-
centrations (0.25 and 0.5 mg/mL) and three positive controls
were used to test the binding among capture antibodies,detection antibodies and antigen or pathogens. The tested
antigen (pathogen) solutions were diluted in a serial concen-
tration with a final 1% BSA TBS solution. Aside from the
purchased Chlamydia trachomatis antigen, which was paired,
all the pathogens were purchased from different sources and
cultured in the laboratory, including Escherichia coli (ATCC
25922), Neisseria gonorrhoeae (from ATCC, ATCC 31426),
Streptococcus agalactiae (BCRC, Bioresource Collection and
Research Center, Taiwan, 10787, ATCC 13813) and Candida
albicans (BCRC 22903, ATCC 90028).Collection of clinical samplesClinical samples from the four patients, who were present
for the clinical diagnosis of vulva-vaginal candidiasis, were
collected following a procedure similar to an ordinary pelvic
examination. A Pap smear was performed, including one for
endocervix and the other for the whole exocervix. Both swabs
were dipped into a tube with 3 mL of normal saline and stirred
up and down five times, and then the sticks with the brush
were discarded. The tubes were stored in a e20C freezer
immediately for future assessment. The study was approved by
the Institutional Review Board (VGH IRB, 2011-02-043IC).Chip assay for clinical samplesChips composed of both 0.25 mg/mL and 0.5 mg/mL
concentrations of capture antibody (without biotin) from five
pathogens and three positive controls, including Cy3-labeled
IgG, goat anti-rabbit IgG, and anti-Escherichia coli IgG with
biotin almost identical to the previous one, were used for
clinical application. The specimens were added to the wells in
four different conditions, with and without spiking attacks of
Candida albicans.Reading of the chipsAfter the chip was dry, it was scanned with Luxscan
(CapitalBio, Beijing, China) and finally analyzed by Genpix.Data analysisA paired Student t test with p < 0.05 was considered
significant.
ResultsValidation of the liposomal amplifying system
Validation on a 96-well plate
Preparation of the ATA-tagged liposome took about 4
hours, and the following conjugation of neutravidin required
another 4 hours and was left overnight. However, a large
amount of modified liposome could be manufactured at a time
and stored for future use. The average time needed to activate
the microarray immunoassay chip system was 3 hours. The
average ELISA fluorescence reading for three replicates was
Printing/block Antibodies Antibodies with Biotin 
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6 Cy3-labeled IgG 
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control. This neutravidin-conjugated liposome amplifying
system could bind to the biotin on the detecting antibody and
showed significant brightness ( p < 0.01) on a 96-well plate
(Fig. 1).
Validation on a chip
Similar validation tests were repeated using chips of pattern
one, i.e., four replicates of five different antibodies with or
without biotin labels and one Cy3-positive control on glass
slides (Fig. 2A). Significant fluorescent signals were detected
on the spots printed with biotin-labeled IgG when little or no
signal was detected on the spots printed with IgG without
biotin (Fig. 2B). Taking Chlamydia trachomatis antibody as an
example, the average intensity reading was 33 and the reading
of the relative negative control was zero (Fig. 4). This
neutravidin-conjugated liposome amplifying system also
showed a significant binding capacity to the biotin on the
detecting antibodies, which were printed on the glass directly
( p < 0.01).Validation of the antigen-antibody reaction on chipsFig. 2. (A) The designed scale of printing pattern 1. (B) Illustration of the
validation principle for the detection system and the chip image showing
strong signal intensity on the right side with spots coated with biotinylated
antibody for every row in the red rectangle. IgG ¼ immunoglobulin G.The best condition for detecting the pathogens cultured and
stored in the laboratory was studied together with different
combinations of detecting antibodies on the chips (Fig. 3A).
Positive signals were recovered for every pathogen (Fig. 3B).
However, better signals were obtained only when a higher
concentration of antibody was used (0.5 mg/mL), especially for
Neisseria gonorrhoeae (1.5 mg/mL). Moreover, only the study
of Chlamydia trachomatis and Candida albicans showed a
significant dose-dependent response for detection. Further-
more, the background on this microarray immunoassay chip for
Chlamydia trachomatis assessment (antibody coated at a con-
centration of 0.25 mg/mL) was 1892  56, which was a rela-
tively noisy, intense fluorescence (3321  251, p < 0.01) at anFig. 1. Validation of conjugation of neutravidin and liposome on a 96-well
plate. The wells coated with purchased immunoglobulin-biotin showed
strong signal intensity (450.7) after reaction with conjugated liposomes
compared with the negative controls (11.7). **p < 0.001.
IgG ¼ immunoglobulin G.antigen concentration of 0.0061 mg/mL. A significant increase
(4403  148, p < 0.01) was also demonstrated when the con-
centration of antigen increased 10-fold (Fig. 4). However,
significantly increased fluorescent intensity (4501  1180 vs.
1924 659, p< 0.01) was identified when the concentration of
Candida albicans reached 4.54  105 CFU/mL, and the in-
tensity of fluorescence increased proportionally (Fig. 5) when
the concentrations of Candida increased from 10-fold
(18276  3177) to 100-fold (38994  7452).Detection of pathogens in patients with and without
vulvar and vaginal symptomsAlthough the other four pathogens (Chlamydia trachomatis,
Escherichia coli, Neisseria gonorrhoeae, and Streptococcus
agalactiae) were not detected in the four patients studied, the
detection of candidiasis infection was promising. When the
amount of Candida albicans reached 2.27  107 CFU/mL, a
Escherichia coli Neisseria gonorrhoeae Streptococcus agalactiae  
Column 1 2 3 4 5 6 7 8 
iloc.Eitna-nitoiBtibbaRitnA1
2 Escherichia coli  0.25 Escherichia coli 0.5 
3 Neisseria gonorrhoeae  1.5 Biotin- Neisseria gonorrhoeae
4 Streptococcus agalactiae 0.25 Streptococcus agalactiae 0.5 
5 Candida albicans 0.25 Candida albicans 0.5 




Fig. 3. Results of the antibodies and pathogens on chips binding test. (A) The pattern used in the binding test. (B) Different signal intensities were detected in the
antibody-pathogen reaction chip assays with different pathogens including Escherichia coli (Row 2 in the left image), Neisseria gonorrhoeae (Row 3 in the middle
image) and Streptococcus agalactiae (Row 4 in the right image). IgG ¼ immunoglobulin G.
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compared with the background fluorescence of 39 (Fig. 6).
The estimated expense of this microarray immunoassay chip
for five pathogens and at most 16 samples was US$ 3, if 200
chips were fabricated at the same time. The average timeFig. 4. The results of the antibody-antigen binding test for Chlamydia tra-
chomatis in the chip assay. Significantly increased fluorescence intensity was
detected when the concentration of Chlamydia trachomatis antigen reached
6.06  10-3 mg/mL. A proportional increase was demonstrated when the
concentration increased 10-fold for the detection of Chlamydia trachomatis.
*p < 0.01 when compared to the previous column. **p < 0.001 when
compared to the previous column.
Fig. 5. The results of the antibody-antigen binding test of Candida albicans in
the chip assay. The sensitivity level for autoclaved Candida albicans reached
4.54  105 CFU/mL. A proportional increase in the intensity of fluorescence
can be seen from the upper table and the lower chip images when the con-
centration of Candida albicans increased 10-fold. The bright spots on row five
circled with red lines represent the capture antibody for Candida albicans in a
concentration of 0.5 mg/mL. *p < 0.01 when compared with the previous
column. **p < 0.001 when compared with the previous column.
Fig. 6. The results of a chip assay for the original vaginal samples and the
spiking of those samples with Candida albicans. Four samples were used and
are shown here. Significant positive signals were demonstrated in 1:1 add-in
samples. * p < 0.01 when compared with the original samples or NC.
**p < 0.001 when compared with the original samples or NC. C ¼ Candida
albicans; NC ¼ negative control; S ¼ specimen.
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needed for a single test was 200 minutes.Discussion
The importance of the rapid and precise diagnosis of lower
genital tract pathogens is well known, but it is sometimes
difficult, as it is costly and the majority of the developing
countries could not offer this service. For example, NAATs are
too expensive and complicated to apply in routine clinical
practice as a point-of-care tool [7,17]. Without prompt and
accurate treatment of lower genital tract infections, subsequent
severe sequelae might occur, such as tubo-ovarian abscess and
infertility. To overcome this limitation, some sensitive and
specific tools mediated through immunoassay have been
developed. Unfortunately, only tools for certain pathogens, for
example, chlamydia or human papilloma virus are available in
the market [16]. In this study, we tested the feasibility of this
multiplexed immunoassay chip, which can be used to detect
five pathogens at the same time, and the results seem to be
acceptable.
The advantages of this multiplexed immunoassay chip in
this study included: (1) relatively low cost, which was only
US$ 3 dollars if 200 tests were fabricated at the same time; (2)
no extra need for the expensive equipment used in NAATs; (3)
rapid assessment (3 hours); and, (4) high sensitivity and
specificity for candidiasis diagnosis.
Although this multiplexed immunoassay chip seems very
promising, some unresolved problems should be mentioned.
Firstly, the antigeneantibody reaction between our chips and
the real pathogens in the female reproductive tract, aside from
candida, is yet to be established. In this study, only candidiasis
was tested, although the results showed good correlation with
a clinical situation. In addition, the Candida strains could not
be differentiated in this chip. Secondly, since normal flora in
the female lower genital tract is complicated and most
importantly, infection of the female lower genital tract is often
caused by multiple pathogens, it is not easy to select the
correct antibodies to be printed on this multiplexed immuno-
assay chip. In fact, it may be necessary to identify the most
common pathogens that cause female genital tract infections
before the design of this multiplexed immunoassay chip, ashow to select the frequent causal pathogen-related antibody for
chip coating is not only one of the most critical steps, but also
the most complicated and difficult one [31]. Furthermore, it is
likely that rapid mutation of these microorganisms with
development of drug resistance makes the selection of a sen-
sitive antibody more and more difficult [32]. Therefore, it is
reported that the discovery of a core antigen specific to the
pathogen and stable from generation to generation is critical
for the success of similar systems [33]; however, instead of
more specific antibodies, such as antilipopolysaccharide anti-
body for chlamydia, only commercialized antibody reagents
were applied in this multiplexed immunoassay chip, which
may have contributed to the lower sensitivity of this multi-
plexed immunoassay chip in the detection of Neisseria gon-
orrhoeae, Streptococcus agalactiae, Chlamydia trachomatis,
and Escherichia coli. Thirdly, the incidence of the above-
mentioned three pathogens might be too low to be detected
in this very small study with only four patients.
Although our previous study showed a sensitivity of
1.0  105 GFU/mL in the detection of multiple pathogens in
water using a liposomal amplifying system [26], the multi-
plexed immunoassay chip showed reduced sensitivity, partly
because G-protein was not used in this protocol. G-protein
induced excess noise in our original design of the multiplexed
immunoassay chip. We used a more complicated bio-
tineantibody binding strategy, liposome-neutravidin conju-
gation, and biotin-neutravidin interaction than the original
G-protein assay, which decreased the intensity of fluorescence
in this multiplexed immunoassay chip. This was due to less
fixation and the crowded space and limited amount of used
substrate on this relatively small chip plain.
Specimens collection from the vagina and cervix might be
another challenge. To simplify the procedure and minimize the
discomfort of patients during speculum examination, a stick
with a brush was used in the sampling procedure, which
caused some problems. Firstly, blood contamination might
have occurred. Secondly, only a minimal amount of discharge
specimen was recovered, especially in the cervical sampling.
Thirdly, a quantitative evaluation was almost impossible since
the sampling amount varied using different brushes.
We believe that this multiplexed immunoassay chip might
be of use in routine practice in the future, especially for
chlamydia and candidiasis, although a further study might be
required. For example, comparison between the conventional
NAATs, culture and this multiplexed immunoassay chip for
the same samples will enable the validation of this multiplexed
immunoassay to be tested.
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